Literature DB >> 20372057

Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.

Jacquelyn J Bower1, Yingchun Zhou, Tong Zhou, Dennis A Simpson, Sonnet J Arlander, Richard S Paules, Marila Cordeiro-Stone, William K Kaufmann.   

Abstract

The decatenation G2 checkpoint is proposed to delay cellular progression from G2 into mitosis when intertwined daughter chromatids are insufficiently decatenated. Previous studies indicated that the ATM- and Rad3-related (ATR) checkpoint kinase, but not the ataxia telangiectasia-mutated (ATM) kinase, was required for decatenation G2 checkpoint function. Here, we show that the method used to quantify decatenation G2 checkpoint function can influence the identification of genetic requirements for the checkpoint. Normal human diploid fibroblast (NHDF) lines responded to the topoisomerase II (topo II) catalytic inhibitor ICRF-193 with a stringent G2 arrest and a reduction in the mitotic index. While siRNA-mediated depletion of ATR and CHEK1 increased the mitotic index in ICRF-193 treated NHDF lines, depletion of these proteins did not affect the mitotic entry rate, indicating that the decatenation G2 checkpoint was functional. These results suggest that ATR and CHEK1 are not required for the decatenation G2 checkpoint, but may influence mitotic exit after inhibition of topo II. A re-evaluation of ataxia telangiectasia (AT) cell lines using the mitotic entry assay indicated that ATM was required for the decatenation G2 checkpoint. Three NHDF cell lines responded to ICRF-193 with a mean 98% inhibition of the mitotic entry rate. Examination of the mitotic entry rates in AT fibroblasts upon treatment with ICRF-193 revealed a significantly attenuated decatenation G2 checkpoint response, with a mean 59% inhibition of the mitotic entry rate. In addition, a normal lymphoblastoid line exhibited a 95% inhibition of the mitotic entry rate after incubation with ICRF-193, whereas two AT lymphoblastoid lines displayed only 36% and 20% inhibition of the mitotic entry rate. Stable depletion of ATM in normal human fibroblasts with short hairpin RNA also attenuated decatenation G2 checkpoint function by an average of 40%. Western immunoblot analysis demonstrated that treatment with ICRF-193 induced ATM autophosphorylation and ATM-dependent phosphorylation of Ser15-p53 and Thr68 in Chk2, but no appreciable phosphorylation of Ser139-H2AX or Ser345-Chk1. The results suggest that inhibition of topo II induces ATM to phosphorylate selected targets that contribute to a G2 arrest independently of DNA damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372057      PMCID: PMC3096717          DOI: 10.4161/cc.9.8.11470

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  58 in total

1.  A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.

Authors:  L H Jensen; K C Nitiss; A Rose; J Dong; J Zhou; T Hu; N Osheroff; P B Jensen; M Sehested; J L Nitiss
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

2.  Cdc7-Dbf4 and the human S checkpoint response to UVC.

Authors:  Timothy P Heffernan; Keziban Unsal-Kaçmaz; Alexandra N Heinloth; Dennis A Simpson; Richard S Paules; Aziz Sancar; Marila Cordeiro-Stone; William K Kaufmann
Journal:  J Biol Chem       Date:  2007-02-02       Impact factor: 5.157

3.  Identification of primary transcriptional regulation of cell cycle-regulated genes upon DNA damage.

Authors:  Tong Zhou; Jeff Chou; Thomas E Mullen; Rani Elkon; Yingchun Zhou; Dennis A Simpson; Pierre R Bushel; Richard S Paules; Edward K Lobenhofer; Patrick Hurban; William K Kaufmann
Journal:  Cell Cycle       Date:  2007-04-19       Impact factor: 4.534

4.  Depletion of topoisomerase IIalpha leads to shortening of the metaphase interkinetochore distance and abnormal persistence of PICH-coated anaphase threads.

Authors:  Jennifer M Spence; Hui Hui Phua; Walter Mills; Adam J Carpenter; Andrew C G Porter; Christine J Farr
Journal:  J Cell Sci       Date:  2007-10-23       Impact factor: 5.285

5.  Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193.

Authors:  Helen M R Robinson; Sigrid Bratlie-Thoresen; Robert Brown; David A F Gillespie
Journal:  Cell Cycle       Date:  2007-05-01       Impact factor: 4.534

6.  Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.

Authors:  William K Kaufmann; Kathleen R Nevis; Pingping Qu; Joseph G Ibrahim; Tong Zhou; Yingchun Zhou; Dennis A Simpson; Jennifer Helms-Deaton; Marila Cordeiro-Stone; Dominic T Moore; Nancy E Thomas; Honglin Hao; Zhi Liu; Janiel M Shields; Glynis A Scott; Norman E Sharpless
Journal:  J Invest Dermatol       Date:  2007-06-28       Impact factor: 8.551

7.  DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells.

Authors:  Sonnet J H Arlander; Bryan T Greene; Cynthia L Innes; Richard S Paules
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  Ataxia telangiectasia-mutated dependent DNA damage checkpoint functions regulate gene expression in human fibroblasts.

Authors:  Tong Zhou; Jeff Chou; Yingchun Zhou; Dennis A Simpson; Feng Cao; Pierre R Bushel; Richard S Paules; William K Kaufmann
Journal:  Mol Cancer Res       Date:  2007-08       Impact factor: 5.852

9.  Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis.

Authors:  Christian R Loehberg; Tiia Thompson; Michael B Kastan; Kirsteen H Maclean; Dean G Edwards; Frances S Kittrell; Daniel Medina; Orla M Conneely; Bert W O'Malley
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

10.  PIASgamma is required for faithful chromosome segregation in human cells.

Authors:  Laura A Díaz-Martínez; Juan F Giménez-Abián; Yoshiaki Azuma; Vincent Guacci; Gonzalo Giménez-Martín; Lorene M Lanier; Duncan J Clarke
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

View more
  12 in total

Review 1.  Mitosis in vertebrates: the G2/M and M/A transitions and their associated checkpoints.

Authors:  Conly L Rieder
Journal:  Chromosome Res       Date:  2011-04       Impact factor: 5.239

2.  Titanium dioxide nanoparticles activate the ATM-Chk2 DNA damage response in human dermal fibroblasts.

Authors:  Raju Y Prasad; Paul D Chastain; Nana Nikolaishvili-Feinberg; Lisa Smeester; William K Kaufmann; Rebecca C Fry
Journal:  Nanotoxicology       Date:  2012-08-23       Impact factor: 5.913

3.  MCPH1 is essential for cellular adaptation to the G2-phase decatenation checkpoint.

Authors:  María Arroyo; Ryoko Kuriyama; Israel Guerrero; Daniel Keifenheim; Ana Cañuelo; Jesús Calahorra; Antonio Sánchez; Duncan J Clarke; J Alberto Marchal
Journal:  FASEB J       Date:  2019-04-09       Impact factor: 5.191

4.  Effective intra-S checkpoint responses to UVC in primary human melanocytes and melanoma cell lines.

Authors:  Marila Cordeiro-Stone; John J McNulty; Christopher D Sproul; Paul D Chastain; Eugene Gibbs-Flournoy; Yingchun Zhou; Craig Carson; Shangbang Rao; David L Mitchell; Dennis A Simpson; Nancy E Thomas; Joseph G Ibrahim; William K Kaufmann
Journal:  Pigment Cell Melanoma Res       Date:  2015-11-03       Impact factor: 4.693

5.  Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.

Authors:  J J Bower; G F Karaca; Y Zhou; D A Simpson; M Cordeiro-Stone; W K Kaufmann
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

6.  Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours.

Authors:  Madushan Fernando; Pascal H G Duijf; Martina Proctor; Alexander J Stevenson; Anna Ehmann; Shivam Vora; Dubravka Skalamera; Mark Adams; Brian Gabrielli
Journal:  Oncogenesis       Date:  2021-05-15       Impact factor: 7.485

7.  Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.

Authors:  Haolong Li; Ning Xie; Martin E Gleave; Xuesen Dong
Journal:  Oncotarget       Date:  2015-08-21

8.  Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.

Authors:  Jacquelyn J Bower; Leah D Vance; Matthew Psioda; Stephanie L Smith-Roe; Dennis A Simpson; Joseph G Ibrahim; Katherine A Hoadley; Charles M Perou; William K Kaufmann
Journal:  NPJ Breast Cancer       Date:  2017-03-31

9.  Direct monitoring of the strand passage reaction of DNA topoisomerase II triggers checkpoint activation.

Authors:  Katherine L Furniss; Hung-Ji Tsai; Jo Ann W Byl; Andrew B Lane; Amit C Vas; Wei-Shan Hsu; Neil Osheroff; Duncan J Clarke
Journal:  PLoS Genet       Date:  2013-10-03       Impact factor: 5.917

Review 10.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.